Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01517100 · ClinicalTrials.gov registry record · Phase 1
The Role of Endocannabinoids in Insulin Production and Action
A Phase 1 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT01517100 is a Phase 1 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 45 participants.
The verdict
NCT01517100, a Phase 1 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
Background: \- The endocannabinoid system is involved in different body functions and processes. It helps regulate appetite and mood, and sends signals to the nervous system. It may also be involved in how the body produces insulin during digestion. Researchers want to test two drugs that work on the endocannabinoid system: nabilone and CP-945,598. These drugs may be able to affect insulin levels in the blood. This information may suggest possible new treatments for people with diabetes. Objectives: \- To study how the endocannabinoid system is involved in insulin production and action. Eligibility: \- Healthy men between 21 and 55 years of age. Design: * Participants will be screened with a physical exam and medical history. They will provide blood and urine samples. They will also have imaging studies to test their brain responses, especially to food-related cues. Some participants will also have a study visit to test their insulin resistance levels. * Participants will have four separate study visits 6 weeks apart. They will keep a food diary before each visit. At each visit, they will have one of the following combinations of drugs: * Double placebo * Placebo and nabilone * Placebo and low dose of CP-945,598 * Placebo and high dose of CP-945,598. * Participants will have follow-up visits 1 week after each study visit. Blood samples will be taken....
Interventions
- DRUG CP-945,598
- OTHER Nabilone
- OTHER hyperglycemic clamp
- OTHER euglycemic-hyperinsulinemic clamp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2012-01-05 |
| Est. Completion | 2014-10-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01517100
The ClinicalTrials.gov registry entry for NCT01517100 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CP-945,598 is the first listed.
NCT01517100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01517100 about?
NCT01517100 is a clinical study titled "The Role of Endocannabinoids in Insulin Production and Action". Background: \- The endocannabinoid system is involved in different body functions and processes. It helps regulate appetite and mood, and sends signals to the nervous system. It may also be involved in how the body produces insulin during digestion. Researchers want to test two drugs that work on t...
What is the current status of trial NCT01517100?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2012-01-05. Estimated completion is 2014-10-06.
What interventions are being tested in trial NCT01517100?
The interventions under investigation include: CP-945,598 (DRUG), Nabilone (OTHER), hyperglycemic clamp (OTHER), euglycemic-hyperinsulinemic clamp (OTHER).
Who is sponsoring clinical trial NCT01517100?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.